Abstract
Thalidomide remains a household name 35 years after the disaster caused by its teratogenic properties. Its use re-emerged when the therapeutic benefit of thalidomide in lepromatous leprosy was recognised, and it continues to be used in a small number of patients with a variety of conditions for whom there is no therapeutic alternative. Thalidomide's unique and numerous pharmacological properties have maintained research interest, most recently concentrating on the inhibition of both tumour necrosis factor and angiogenesis. These may be important pharmacological mechanisms in those clinical conditions where it has proven therapeutic benefit. Thalidomide is beneficial in idiopathic oral and genital ulceration, and the similar ulceration of Behcet's disease and human immunodeficiency virus (HIV) infection. In addition, it is of value in chronic graft-versus-host disease, lepromatous leprosy and in a number of rare dermatoses. However, the current use of thalidomide is overshadowed by the tragedy of around 12...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
